Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$251.65
-0.7%
$233.96
$160.36
▼
$261.00
$37.03B0.11.25 million shs839,661 shs
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$511.48
+2.5%
$454.92
$353.99
▼
$556.52
$104.58B1.111.45 million shs1.05 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
0.00%+2.03%+8.92%+21.16%+51.24%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
0.00%+0.89%+8.82%+23.00%+5.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$251.65
-0.7%
$233.96
$160.36
▼
$261.00
$37.03B0.11.25 million shs839,661 shs
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$511.48
+2.5%
$454.92
$353.99
▼
$556.52
$104.58B1.111.45 million shs1.05 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
0.00%+2.03%+8.92%+21.16%+51.24%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
0.00%+0.89%+8.82%+23.00%+5.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$254.411.10% Upside
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
2.63
Moderate Buy$480.13-6.13% Downside

Current Analyst Ratings Breakdown

Latest BIIB and HCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
UpgradeBuy (B-) ➝ Buy (B)
11/9/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingOverweight$245.00 ➝ $305.00
11/3/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Reiterated RatingBuy$495.00 ➝ $510.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$280.00 ➝ $300.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$251.00 ➝ $270.00
11/2/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Boost Price TargetEqual Weight$381.00 ➝ $468.00
10/30/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Boost Price TargetOutperform$496.00 ➝ $521.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
DowngradeHold (C) ➝ Hold (C-)
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetOutperform$256.00 ➝ $272.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetNeutral$212.00 ➝ $225.00
10/29/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$270.00 ➝ $300.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.76$22.73 per share11.07$128.01 per share1.97
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$75.60B1.41$46.20 per share11.07($22.02) per share-23.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.3421.2615.792.843.37%9.38%5.69%N/A
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$6.78B$30.1816.7016.251.678.61%-198.52%10.81%1/26/2027 (Estimated)

Latest BIIB and HCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
10/27/2026Q3 2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$6.65$7.22+$0.57$7.27$19.33 billion$19.85 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$3.120.61%+30.19%10.34%6 Years

Latest BIIB and HCA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
quarterly$0.780.69%12/15/202612/15/202612/29/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
N/A
0.82
0.74

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
62.73%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
320,000208.89 million205.76 millionOptionable

Recent News About These Companies

Healthcare Stocks Rise at the Open as AI Hardware Names Slide
Zacks Research Estimates HCA Healthcare FY2026 Earnings
FY2026 EPS Estimate for HCA Healthcare Boosted by Analyst
Insider Selling: HCA Healthcare (NYSE:HCA) SVP Sells $1,770,335.00 in Stock
What Really Drove HCA Stock Higher?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biogen stock logo

Biogen NASDAQ:BIIB

$251.65 -1.75 (-0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$253.00 +1.35 (+0.54%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

HCA Healthcare stock logo

HCA Healthcare NYSE:HCA

$511.48 +12.43 (+2.49%)
Closing price 03:59 PM Eastern
Extended Trading
$508.42 -3.06 (-0.60%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.